Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Incyte Corporation, Mallinckrodt plc, and Syndax Pharmaceuticals Inc.

Medical Crossfire®: Exploring Novel Agents and Future Directions in GVHD Management

Release Date: June 22, 2020
Expiration Date: June 22, 2021

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of graft-versus-host disease (GVHD) and how new and novel agents might impact clinical practice. Diagnosis, prophylaxis, and emerging therapeutic strategies for acute and chronic GVHD are presented in the format of a panel discussion between thought-leaders in the field of GVHD.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Incyte Corporation, Mallinckrodt plc, and Syndax Pharmaceuticals Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward hematologists, medical oncologists, researchers and investigators who treat or are interested in the treatment of hematologic malignancies. Other allied health care professionals, including nurse practitioners, physician assistants, and nurses involved in the treatment and management of patients with hematologic malignancies, are also invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Explain the pathogenesis and diagnostic criteria of GVHD in the context of facilitating identification and management
  • Outline current prophylactic and treatment regimens for GVHD
  • Determine emerging approaches for the management of GVHD
  • Implement strategies to identify and manage treatment-related toxicities associated with GVHD care strategies

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Madan H. Jagasia, MBBS, MSCI, MMHC
Madan H. Jagasia, MBBS, MSCI, MMHC
Chief Medical Officer, Vanderbilt-Ingram Cancer Center
Co-Leader, Translational Research and Interventional Oncology Research Program
Professor of Medicine, Division of Hematology-Oncology
Vanderbilt University Medical Center
Nashville, TN

Disclosures: Consultant/Advisor: Incyte Corporation, Novartis AG, Kadmon Holdings, Inc, Mallinckrodt plc, Occugen Inc.

James L. M. Ferrara, MD, DSc
James L. M. Ferrara, MD, DSc
Ward-Coleman Chair in Cancer Medicine
Professor of Medicine and Pediatrics
Director, Hematologic Malignancies Translational Research Center
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Other: Patent for Biomarkers of Acute GVHD: IC Licensed to ViraCor Eurofins Laboratories.

Mark A. Schroeder, MD, MSCI
Mark A. Schroeder, MD, MSCI
Associate Professor of Medicine
Division of Oncology
Section of Bone Marrow Transplant and Leukemia
Washington University School of Medicine in St. Louis
Saint Louis, MO

Disclosures: Grant Research Support: Incyte Corporation, Janssen Pharmaceuticals Inc; Consultant: GlaxoSmithKline plc, Dova Pharmaceuticals Inc, Flatiron Health Inc; Speakers Bureau: AbbVie Inc, Merck & Co, Inc, Takeda Pharmaceutical Company Limited (All terminated 08/2019).

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By